Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 165Other solid neoplasm 2Breast 1

Conditions

Breast Neoplasms 13110Triple Negative Breast Neoplasms 1145Neoplasms 748Ovarian Neoplasms 676Neoplasm Metastasis 588Lung Neoplasms 581Colorectal Neoplasms 576Prostatic Neoplasms 559Carcinoma, Non-Small-Cell Lung 533Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 349Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 265Head and Neck Neoplasms 265Endometrial Neoplasms 254Carcinoma, Renal Cell 215Sarcoma 202Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 190Lymphedema 190Breast Carcinoma In Situ 189Esophageal Neoplasms 188Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Breast Cancer Female 148

Interventions

Pemetrexed 1Paclitaxel 1Drug Therapy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × Breast × Clear all
NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 2 Not yet recruiting
148 enrolled
BreastThoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡